| Company Name: |
Shanghai YuanYe Biotechnology Co., Ltd.
|
| Tel: |
021-61312847; 18021002903 |
| Email: |
3008007409@qq.com |
| Products Intro: |
Product Name:Ianalumab (anti-TNFRSF13C)
CAS:1929549-92-7
Purity:Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human I Package:5mg Remarks:K10827
|
| Company Name: |
ShangHai Biochempartner Co.,Ltd
|
| Tel: |
177-54423994 17754423994 |
| Email: |
2853530910@QQ.com |
| Products Intro: |
Product Name:Ianalumab
CAS:1929549-92-7
Purity:95% Package:100ug;500ug;1mg
|
| Company Name: |
Guangzhou Hongyuan Chemical Co.,Ltd
|
| Tel: |
15817493340 |
| Email: |
981810490@qq.com |
| Products Intro: |
Product Name:Ianalumab
CAS:1929549-92-7
Purity:95% Package:1mg;1g;100g
|
Ianalumab manufacturers
- Ianalumab
-
- $222.00
-
2026-05-21
- CAS:1929549-92-7
- Purity: 100% (SEC-HPLC)
- Supply Ability: 10g
|
| | Ianalumab Basic information |
| Product Name: | Ianalumab | | Synonyms: | Ianalumab;Research Grade Ianalumab (DHJ42201);Ianalumab (anti-TNFRSF13C);VAY-736;Research Grade Ianalumab | | CAS: | 1929549-92-7 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Ianalumab Structure]() |
| | Ianalumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Ianalumab Usage And Synthesis |
| Uses | Ianalumab (VAY-736) is a human, decarboxylated antibody against BAFF-R. Ianalumab can block the interaction between BAFF and BAFF-R and antagonize the apoptosis protection mediated by BAFF. Ianalumab exerts antibody-dependent cytotoxic (ADCC), depending on effector cell activation mediated by immune receptor tyrosine activation motif (ITAM)[1]. | | in vivo | Ianalumab (Total: 100 mg/kg; once weekly for 2 weeks) increases in vivo survival in CLL mouse models[1].
Ianalumab (10 mg/kg; once weekly for 6 weeks) is enhanced by Ibrutinib (HY-10997) through an ITAM function on NK cells[1]. | Animal Model: | Em-TCL1 adoptive transplant model of murine CLL[1] | | Dosage: |
10 mg/kg | | Administration: |
Injection; once weekly for 6 weeks | | Result: | Ibrutinib enhanced VAY-736 activity through an ITAM function on NK cells.
|
| | References | [1] McWilliams EM, et al. Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib. Blood Adv. 2019 Feb 12;3(3):447-460. DOI:10.1182/bloodadvances.2018025684 |
| | Ianalumab Preparation Products And Raw materials |
|